JP6168420B2 - 全身麻酔薬と、水素とを組み合わせてなる、医薬 - Google Patents

全身麻酔薬と、水素とを組み合わせてなる、医薬 Download PDF

Info

Publication number
JP6168420B2
JP6168420B2 JP2014518736A JP2014518736A JP6168420B2 JP 6168420 B2 JP6168420 B2 JP 6168420B2 JP 2014518736 A JP2014518736 A JP 2014518736A JP 2014518736 A JP2014518736 A JP 2014518736A JP 6168420 B2 JP6168420 B2 JP 6168420B2
Authority
JP
Japan
Prior art keywords
anesthetic
hydrogen
general
medicament
hydrogen gas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014518736A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2013180240A1 (ja
Inventor
富栄 風間
富栄 風間
佐藤　泰司
泰司 佐藤
龍二 与那嶺
龍二 与那嶺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maruishi Pharmaceutical Co Ltd
Original Assignee
Maruishi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruishi Pharmaceutical Co Ltd filed Critical Maruishi Pharmaceutical Co Ltd
Priority to JP2014518736A priority Critical patent/JP6168420B2/ja
Publication of JPWO2013180240A1 publication Critical patent/JPWO2013180240A1/ja
Application granted granted Critical
Publication of JP6168420B2 publication Critical patent/JP6168420B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014518736A 2012-05-31 2013-05-30 全身麻酔薬と、水素とを組み合わせてなる、医薬 Expired - Fee Related JP6168420B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014518736A JP6168420B2 (ja) 2012-05-31 2013-05-30 全身麻酔薬と、水素とを組み合わせてなる、医薬

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012125535 2012-05-31
JP2012125535 2012-05-31
PCT/JP2013/065094 WO2013180240A1 (ja) 2012-05-31 2013-05-30 全身麻酔薬と、水素とを組み合わせてなる、医薬
JP2014518736A JP6168420B2 (ja) 2012-05-31 2013-05-30 全身麻酔薬と、水素とを組み合わせてなる、医薬

Publications (2)

Publication Number Publication Date
JPWO2013180240A1 JPWO2013180240A1 (ja) 2016-01-21
JP6168420B2 true JP6168420B2 (ja) 2017-07-26

Family

ID=49673427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014518736A Expired - Fee Related JP6168420B2 (ja) 2012-05-31 2013-05-30 全身麻酔薬と、水素とを組み合わせてなる、医薬

Country Status (16)

Country Link
US (1) US20150079197A1 (enExample)
EP (1) EP2857026A4 (enExample)
JP (1) JP6168420B2 (enExample)
KR (1) KR20150018832A (enExample)
CN (1) CN104394873A (enExample)
AU (1) AU2013268366A1 (enExample)
BR (1) BR112014029260A2 (enExample)
CA (1) CA2874579A1 (enExample)
HK (1) HK1205450A1 (enExample)
IL (1) IL235718A0 (enExample)
IN (1) IN2014MN02090A (enExample)
MX (1) MX2014014543A (enExample)
NZ (1) NZ701553A (enExample)
RU (1) RU2014152690A (enExample)
SG (1) SG11201407489TA (enExample)
WO (1) WO2013180240A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6253029B2 (ja) * 2015-01-21 2017-12-27 大陽日酸株式会社 麻酔器用取付キット
US20180338995A1 (en) * 2017-05-23 2018-11-29 Perricone Hydrogen Water Company, Llc Systems and methods for treatments using hydrogen and/or noble gases
US11129848B2 (en) * 2017-08-08 2021-09-28 Perricone Hydrogen Water Company, Llc Medication enhancement using hydrogen
US20210222174A1 (en) * 2018-06-29 2021-07-22 John Mansell Compositions and methods for the treatment of anesthesia-induced neurotoxicity
US11123365B2 (en) 2019-11-18 2021-09-21 Perricone Hydrogen Water Company, Llc Compositions comprising palmitoylethanolamide and hydrogen water, and methods thereof
JP7019910B2 (ja) * 2020-07-21 2022-02-16 ＭｉＺ株式会社 薬の副作用、薬の副作用に関連する症状、および／または、治療に伴う副作用を予防および／または改善するための組成物
CN117861037A (zh) * 2022-10-11 2024-04-12 上海氢医医疗科技有限公司 氢气吸入治疗自闭症
CN119303200A (zh) * 2024-12-17 2025-01-14 山东百多安医疗器械股份有限公司 一种可以释放氢气减少神经损伤的麻醉机

Also Published As

Publication number Publication date
KR20150018832A (ko) 2015-02-24
CA2874579A1 (en) 2013-12-05
WO2013180240A1 (ja) 2013-12-05
EP2857026A4 (en) 2015-11-04
US20150079197A1 (en) 2015-03-19
BR112014029260A2 (pt) 2017-06-27
SG11201407489TA (en) 2014-12-30
MX2014014543A (es) 2015-06-05
IN2014MN02090A (enExample) 2015-09-04
NZ701553A (en) 2016-06-24
RU2014152690A (ru) 2016-07-20
IL235718A0 (en) 2015-01-29
EP2857026A1 (en) 2015-04-08
AU2013268366A1 (en) 2015-03-19
JPWO2013180240A1 (ja) 2016-01-21
HK1205450A1 (en) 2015-12-18
CN104394873A (zh) 2015-03-04

Similar Documents

Publication Publication Date Title
JP6168420B2 (ja) 全身麻酔薬と、水素とを組み合わせてなる、医薬
Perez-Zoghbi et al. Dexmedetomidine-mediated neuroprotection against sevoflurane-induced neurotoxicity extends to several brain regions in neonatal rats
Lee et al. Effects of systemic administration of ibuprofen on stress response in a rat model of post-traumatic stress disorder
Karen et al. Effect of propofol in the immature rat brain on short-and long-term neurodevelopmental outcome
Parameshwaran et al. Developmental nicotine exposure induced alterations in behavior and glutamate receptor function in hippocampus
Sun et al. Gastrodin relieved complete Freund's adjuvant-induced spontaneous pain by inhibiting inflammatory response
Siopi et al. Etazolate, an α-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice
Guimarães et al. Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial
Cao et al. Role of early environmental enrichment on the social dominance tube test at adulthood in the rat
Kim et al. P2X7 receptor differentially modulates astroglial apoptosis and clasmatodendrosis in the rat brain following status epilepticus
Britton et al. Perinatal nicotine exposure eliminates peak in nicotinic acetylcholine receptor response in adolescent rats
JP2024533015A (ja) 脱髄性の疾患および病状の処置のためのフェンフルラミン
Flores et al. Neonatal olfactory bulbectomy enhances locomotor activity, exploratory behavior and binding of NMDA receptors in pre-pubertal rats
Harding et al. Prenatal exposure to valproic acid and treatment with intranasal oxytocin have sex-specific effects on behavior in Long Evans rats
Ju et al. Increasing the interval between repeated anesthetic exposures reduces long‐lasting synaptic changes in late post‐natal mice
Ribeiro et al. A single intraperitoneal injection of ketamine does not affect spatial working, reference memory or neurodegeneration in adult mice: an animal study
Wei et al. Bumetanide attenuates sevoflurane‐induced neuroapoptosis in the developing dentate gyrus and impaired behavior in the contextual fear discrimination learning test
Li et al. Interferon-induced transmembrane protein 3 in the hippocampus: a potential novel target for the therapeutic effects of recombinant human brain natriuretic peptide on sepsis-associated encephalopathy
Blaylock The danger of excessive vaccination during brain development the case for a link to autism spectrum disorders
Volkow Marijuana
US20180318338A1 (en) Methods and compositions for the prevention of suicide, homicide and self-harming behaviors
Talty et al. Mild traumatic brain injury gives rise to chronic depression-like behavior and associated alterations in glutamatergic protein expression
Qi et al. Depressive‐like history alters persistent pain behavior in rats: Opposite contribution of frontal cortex and amygdala implied
Wesely The Influence of Prenatal THC and Nicotine Exposure via Vapor Inhalation on Offspring Motor Coordination
Maurer Dietary Choline, Inflammation, and Neuroprotection Across the Lifespan.

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170517

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170523

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170615

R150 Certificate of patent or registration of utility model

Ref document number: 6168420

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees